"First in Human" documentary features CCR physician-scientists

The National Cancer Institute's Center for Cancer Research is proud to be a part of "First in Human", a documentary capturing the real-life experiences of doctors, researchers, staff, patients and their caregivers at the NIH Clinical Center. Our CCR physician-scientists are dedicated to leading cutting-edge clinical trials aimed at discovering new and better treatments for cancer. The CCR’s clinical program is the largest of NIH programs housed at the Clinical Center, and we are proud of our history of success. But none of it would be possible without our patients, like Bo, Anita and Lucy. With deep respect, we salute their courage and thank them. Learn more...

"First in Human" documentary features CCR physician-scientists

Recap: “First in Human” Twitter chat

Posted: Aug 17, 2017

Leading up to the premiere of the three-part documentary, First in Human, Discovery hosted a Twitter chat on Wednesday, August 9, 2017, to discuss clinical trials and the making of the film. Stephanie Goff, M.D., Staff Clinician in the Surgery Branch, and Terry Fry, M.D., Investigator in the Pediatric Oncology Branch, represented the Center for Cancer Research in the chat. This Storify post recaps the chat and gives the audience an inside look at the making of the documentary.

Recap: “First in Human” Twitter chat

CAR T-Cell therapy can lead to long-lasting remissions in patients with lymphoma

Posted: Aug 17, 2017

More than three years after treatment, some clinical trial participants who received CAR T-cell therapy for diffuse large B-cell lymphoma remain in remission. These results are reported in a paper in Molecular Therapy by James Kochenderfer, M.D., of CCR's Experimental Transplantation and Immunology Branch. “This raises the possibility that CAR T cells can be curative for diffuse large B cell lymphoma,” Kochenderfer says.

CAR T-Cell therapy can lead to long-lasting remissions in patients with lymphoma

Kevin Camphausen awarded ASTRO Fellowship

Posted: Aug 16, 2017

Kevin Camphausen, M.D., Chief of CCR’s Radiation Oncology Branch, is among 23 distinguished members of the American Society for Radiation Oncology (ASTRO) to receive fellowship designation. Since 2006, the ASTRO Fellowship has been awarded to physicians and medical physicists making significant contributions to the field of radiation oncology in research, patient care, education and leadership. Dr. Camphausen will receive his award during ASTRO’s Annual Meeting, held September 24-27, 2017, in San Diego.

Kevin Camphausen awarded ASTRO Fellowship

Clinical trial tests drug for tumors associated with Krebs-cycle dysfunction

Posted: Aug 15, 2017

The Krebs cycle is part of the complex process where cells turn food into energy. One of the elements of the Krebs cycle is succinate dehydrogenase (SDH). Loss of SDH activity in cells has been linked to tumor formation. This new trial is studying guadecitabine for tumors associated with Krebs cycle dysfunction. Learn more...

Clinical trial tests drug for tumors associated with Krebs-cycle dysfunction

CCR scientists gain new understanding of cellular mechanisms during infection

Posted: Aug 14, 2017

A new study published August 10, 2017, in Molecular Cell reveals how changes in the architecture of the nucleus can enable B lymphocytes to spring to action during an immune system attack and help fight infection. The discovery could lead scientists to a better understanding of how some tumor cells, especially blood cancer cells, make similar transitions from a dormant to an active state. Read more. . .

CCR scientists gain new understanding of cellular mechanisms during infection

NCI interns participate in NIH annual Summer Intern Poster Day

Posted: Aug 11, 2017

After a summer of hard work, over 250 NCI summer interns presented their cancer research on August 10, 2017, at the NIH annual Summer Intern Poster Day. Part of the NIH Summer Internship Program in Biomedical Research, students were placed across NCI and other institutes to further their education and develop valuable skills in biomedical technology. NIH offers several summer internship opportunities to students of various educational backgrounds and interests. 

NCI interns participate in NIH annual Summer Intern Poster Day

Freddy Escorcia appointed as Assistant Clinical Investigator

Posted: Aug 9, 2017

Freddie Escorcia, M.D., Ph.D., has been appointed as an Assistant Clinical Investigator in the Molecular Imaging Program (MIP). Dr. Escorcia's work focuses on tumor-targeted, personalized cancer treatment. Targeted radionuclide therapy provides an orthogonal mode of cell killing that is distinct from, yet complementary to, existing small molecule and chemotherapy treatments.  Learn more...

Freddy Escorcia appointed as Assistant Clinical Investigator

Keeping genome organized creates opportunities for damage

Posted: Aug 7, 2017

Packing an entire genome inside the cramped quarters of a cell nucleus can put chromosomes at risk for damage, according to new research led by André Nussenzweig, Ph.D., Chief of CCR’s Laboratory of Genomic Integrity. The findings, reported July 20, 2017, in Cell, suggest that DNA breaks are routinely introduced and then repaired as a cell folds and organizes its genome, and that when repair processes fail, these breaks can give rise to chromosomal abnormalities characteristic of cancer cells. 

Keeping genome organized creates opportunities for damage

New study identifies essential genes for cancer immunotherapy

Posted: Aug 7, 2017

Nicholas Restifo, M.D., Senior Investigator in CCR’s Surgery Branch, published a new study in Nature on August 7, 2017, and was featured in an NCI Press Release. This new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don’t respond to immunotherapy or respond initially but then stop as tumor cells develop resistance to immunotherapy.

Dr. Restifo said in the press release, “There is a great deal of interest in cancer immunotherapy, especially for patients who have metastatic cancer. The response to immunotherapy can be fantastic, but understanding why some patients don’t respond will help us improve treatments for more patients.”

New study identifies essential genes for cancer immunotherapy

Trial opens to evaluate experimental cancer drug against solid tumors

Posted: Aug 2, 2017

Chemotherapy drugs have long been the mainstay of treatment for advanced solid tumors, but the toxic side effects of these drugs often limit the amount that can safely be given to patients. Doctors hope that PEN-866, an experimental cancer drug, can help to overcome this difficulty. Anish Thomas, M.D., who is leading this new trial, says, “This is a first-of-its-kind approach to facilitate tumor targeted delivery of chemotherapy drugs, which, if successful, would be a big step forward for cancer therapy.” Learn more...

Trial opens to evaluate experimental cancer drug against solid tumors

Pages